427
Views
19
CrossRef citations to date
0
Altmetric
Drug Profile

Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa

&
Pages 523-530 | Received 03 Jan 2018, Accepted 13 Jun 2018, Published online: 26 Jun 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Cristiana M. Nascimento-Carvalho. (2021) Delafloxacin as a treatment option for community-acquired pneumonia infection. Expert Opinion on Pharmacotherapy 22:15, pages 1975-1982.
Read now
Ying Li, Yousheng Yin, Xiaomei Peng, Hongguang Zheng, Fajun Fu, Zhenxiang Liu, Xiongfei Wu, Xiaoyan Wu, Song Zheng, Nan Chen, Leye He, Laicheng Ren, Zhaohui Ni, Detian Li, Peiyu Liang, Xiaoju Lv & Yingyuan Zhang. (2021) A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infection. Annals of Medicine 53:1, pages 217-226.
Read now
Matteo Bassetti, Maddalena Peghin, Nadia Castaldo & Daniele Roberto Giacobbe. (2019) The safety of treatment options for acute bacterial skin and skin structure infections. Expert Opinion on Drug Safety 18:8, pages 635-650.
Read now

Articles from other publishers (16)

Shivani Juneja, Rohit Kalia, Ratinder P Singh & Vandana Roy. (2023) Staphylococcus Infections and Emerging Drug Resistance: A Global Concern. Journal of Medical Academics 6:1, pages 20-27.
Crossref
Kalinga Pavan T. Silva, Ganesh Sundar & Anupama Khare. (2023) Efflux pump gene amplifications bypass necessity of multiple target mutations for resistance against dual-targeting antibiotic. Nature Communications 14:1.
Crossref
Sofia Maraki, Viktoria Eirini Mavromanolaki, Dimitra Stafylaki, Evangelia Iliaki-Giannakoudaki & George Hamilos. (2023) In Vitro Activities of Ceftobiprole, Dalbavancin, Tedizolid and Comparators against Clinical Isolates of Methicillin-Resistant Staphylococcus aureus Associated with Skin and Soft Tissue Infections. Antibiotics 12:5, pages 900.
Crossref
Gautam Kumar & Asha Kiran Tudu. (2023) Tackling multidrug-resistant Staphylococcus aureus by natural products and their analogues acting as NorA efflux pump inhibitors. Bioorganic & Medicinal Chemistry 80, pages 117187.
Crossref
Stephen J. Wood, Timothy M. Kuzel & Sasha H. Shafikhani. (2023) Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics. Cells 12:1, pages 199.
Crossref
Jürgen Panholzer, Matthias Neuboeck, Guangyu Shao, Sven Heldt, Markus Winkler, Paul Greiner, Norbert Fritsch, Bernd Lamprecht & Helmut Salzer. (2022) Ciprofloxacin-Resistant Pseudomonas aeruginosa Lung Abscess Complicating COVID-19 Treated with the Novel Oral Fluoroquinolone Delafloxacin. Case Reports in Pulmonology 2022, pages 1-5.
Crossref
Luyan ShenLixiang WangCong LiuShaomin ShiTai TakahashiTiejun Wang. (2021) Community-acquired pneumonia: Trends in and research on drug resistance and advances in new antibiotics. BioScience Trends 15:5, pages 266-275.
Crossref
Aura Rusu, Ioana-Andreea Lungu, Octavia-Laura Moldovan, Corneliu Tanase & Gabriel Hancu. (2021) Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones—Shaping the Fifth Generation. Pharmaceutics 13:8, pages 1289.
Crossref
Beverley Cherie Millar, John McCaughan, Jacqueline C. Rendall & John E. Moore. (2020) Delafloxacin––A novel fluoroquinolone for the treatment of ciprofloxacin‐resistant Pseudomonas aeruginosa in patients with cystic fibrosis . The Clinical Respiratory Journal 15:1, pages 116-120.
Crossref
Dima Ibrahim, Jean-Francois Jabbour & Souha S. Kanj. (2020) Current choices of antibiotic treatment for Pseudomonas aeruginosa infections. Current Opinion in Infectious Diseases 33:6, pages 464-473.
Crossref
Boris Garber & Jonathan Glauser. (2020) Recent Developments in Infectious Disease Chemotherapy: Review for Emergency Department Practitioners 2020. Current Emergency and Hospital Medicine Reports 8:3, pages 116-121.
Crossref
Mark S. Butler & David L. Paterson. (2020) Antibiotics in the clinical pipeline in October 2019. The Journal of Antibiotics 73:6, pages 329-364.
Crossref
Samuel Yeroushalmi, Joshua Yoseph Shirazi & Adam Friedman. (2020) New Developments in Bacterial, Viral, and Fungal Cutaneous Infections. Current Dermatology Reports 9:2, pages 152-165.
Crossref
Jean-Francois Jabbour, Sima L. Sharara & Souha S. Kanj. (2020) Treatment of multidrug-resistant Gram-negative skin and soft tissue infections. Current Opinion in Infectious Diseases 33:2, pages 146-154.
Crossref
Yang Liu, Yan Zhang, Wanyu Zhao, Xiaolei Liu, Fengjuan Hu & Birong Dong. (2019) Pharmacotherapy of Lower Respiratory Tract Infections in Elderly—Focused on Antibiotics. Frontiers in Pharmacology 10.
Crossref
Burkhard Tümmler. (2019) Emerging therapies against infections with Pseudomonas aeruginosa. F1000Research 8, pages 1371.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.